In lung cancer, AXL was identified as a potential target for overcoming EGFR inhibitor resistance and combination of an AXL specific inhibitor (SGI-7079) with Erlotinib reversed Erlotinib resistance in a xenograft model of mesenchymal non-small cell lung cancer [45]. Here, EGFR is linked to lung carcinoma.